Elisa Rumi

Active 2004–2025

93
Papers
19,221
Citations
65
h-index
92
i10-index

Citations

Citations per year for Elisa Rumi2005: 4 citations2006: 9 citations2007: 25 citations2008: 52 citations2009: 52 citations2010: 52 citations2011: 85 citations2012: 131 citations2013: 156 citations2014: 218 citations2015: 234 citations2016: 235 citations2017: 150 citations2018: 162 citations2019: 516 citations2020: 701 citations2021: 629 citations2022: 531 citations2023: 301 citations2024: 598 citations2025: 180 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 991 citing papers, 24.3% of this breakdownItaly: 516 citing papers, 12.7% of this breakdownGermany: 316 citing papers, 7.8% of this breakdownUnited Kingdom: 310 citing papers, 7.6% of this breakdownFrance: 269 citing papers, 6.6% of this breakdownSpain: 172 citing papers, 4.2% of this breakdownCanada: 121 citing papers, 3% of this breakdownAustria: 104 citing papers, 2.6% of this breakdownChina: 104 citing papers, 2.5% of this breakdownAustralia: 92 citing papers, 2.3% of this breakdownSwitzerland: 91 citing papers, 2.2% of this breakdownJapan: 85 citing papers, 2.1% of this breakdown
0%24.3%Other 22.1%

Fields

  • Medicine90.9%
  • Biochemistry, Genetics and Molecular Biology6.1%
  • Immunology and Microbiology2.1%
  • Environmental Science0.2%
  • Other0.7%

Topics

  • Myeloproliferative Neoplasms: Diagnosis and Treatment25.1%
  • Acute Myeloid Leukemia Research15%
  • Kruppel-like factors research9.6%
  • Eosinophilic Disorders and Syndromes8.2%
  • Chronic Myeloid Leukemia Treatments6.9%
  • Hemoglobinopathies and Related Disorders1.8%
  • Other33.4%

Coauthors

All papers

Open in search
  1. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 532

  2. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alessandro Maria Vannucchi, Tiziano Barbui - New England Journal of Medicine 2012 cited by 820

  3. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 1,972

  4. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Authors: , , , , , , , , , , , , , - Blood 2009 cited by 968

  5. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

    Authors: , , , , , , , , , , , - Blood 2008 cited by 1,237

  6. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

    Authors: , , , , , , , , , , , , , , , , - Blood 2012 cited by 589

  7. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2017 cited by 334

  8. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 116

  9. Mutations and prognosis in primary myelofibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nicholas C.P. Cross, Ayalew Tefferi - Leukemia 2013 cited by 746

  10. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2013 cited by 677

  11. Clinical significance of somatic mutation in unexplained blood cytopenia

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 469

  12. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

    Authors: , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2015 cited by 268

  13. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

    Authors: , , , , , , , , , , , , , , , - Blood 2011 cited by 447

  14. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi - NEJM Evidence 2023 cited by 51

  15. Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 538

  16. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

    Authors: , , , , , , , , , , , , - Leukemia 2010 cited by 360

  17. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mario Cazzola, Valerio De Stefano, Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi - American Journal of Hematology 2019 cited by 72

  18. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , - Leukemia 2015 cited by 287

  19. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi - The Lancet Haematology 2021 cited by 132

  20. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2014 cited by 308

  21. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 273

  22. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

    Authors: , , , , , , , , , , , , , , , - Blood 2014 cited by 158

  23. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

    Authors: , , , , , , , , , , , , , , - Blood Cancer Journal 2020 cited by 57

  24. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis

    Authors: , , , , , , - Blood 2010 cited by 186